Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547586 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT00547586 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 122 participants.
The verdict
NCT00547586, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD).
Interventions
- OTHER placebo
- DRUG N-methylnaltrexone bromide (MOA-728)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547586
The ClinicalTrials.gov registry entry for NCT00547586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00547586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547586 about?
NCT00547586 is a clinical study titled "Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain". The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD).
What is the current status of trial NCT00547586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2007-10. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00547586?
The interventions under investigation include: placebo (OTHER), N-methylnaltrexone bromide (MOA-728) (DRUG).
Who is sponsoring clinical trial NCT00547586?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.